Disease-free and overall survival at 3.5 years for...

Annals of Oncology 2017 / 04

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

Earl, H. M., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A-L., Gounaris, I., Abraham, J., Hughes-Davies, L., McAdam8, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartl
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx173
Date:
April, 2017
File:
PDF, 2.51 MB
english, 2017
Conversion to is in progress
Conversion to is failed